Jpmorgan Chase & CO Allovir, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Allovir, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 30,184 shares of ALVR stock, worth $22,939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,184
Previous 364,917
91.73%
Holding current value
$22,939
Previous $248,000
91.13%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALVR
# of Institutions
80Shares Held
49.1MCall Options Held
385KPut Options Held
2.3K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$8.58 Million0.24% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$5.01 Million0.27% of portfolio
-
Octagon Capital Advisors LP New York, NY4.2MShares$3.19 Million0.5% of portfolio
-
Black Rock Inc. New York, NY3.39MShares$2.57 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.94MShares$2.24 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $70.7M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...